KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Invested Capital (2016 - 2025)

Historic Invested Capital for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $27.4 million.

  • TherapeuticsMD's Invested Capital rose 129.18% to $27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year increase of 129.18%. This contributed to the annual value of $27.4 million for FY2024, which is 654.56% down from last year.
  • Per TherapeuticsMD's latest filing, its Invested Capital stood at $27.4 million for Q3 2025, which was up 129.18% from $27.3 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Invested Capital ranged from a high of $174.5 million in Q1 2021 and a low of -$42.4 million during Q3 2021
  • Its 5-year average for Invested Capital is $37.3 million, with a median of $28.7 million in 2024.
  • In the last 5 years, TherapeuticsMD's Invested Capital soared by 48596.64% in 2021 and then plummeted by 6430.95% in 2022.
  • Quarter analysis of 5 years shows TherapeuticsMD's Invested Capital stood at $94.6 million in 2021, then tumbled by 62.87% to $35.1 million in 2022, then decreased by 16.66% to $29.3 million in 2023, then dropped by 6.55% to $27.4 million in 2024, then rose by 0.27% to $27.4 million in 2025.
  • Its Invested Capital stands at $27.4 million for Q3 2025, versus $27.3 million for Q2 2025 and $26.7 million for Q1 2025.